接受肿瘤坏死因子拮抗剂长期治疗患者的乙型肝炎病毒再激活和肝毒性发生率
该回顾性队列研究纳入2001至2010年Kaiser Permanente北加州数据库8887例因自身免疫病开始接受TNF拮抗剂治疗的成人患者,随访至2012年12月。基线HBsAg阳性者中39%发生HBV再激活,而HBsAg阴性且抗-HBc阳性者无再激活。作者建议抗TNF治疗前筛查HBV,HBsAg阳性者应接受预防性抗病毒治疗,HBsAg阴性且抗-HBc阳性者则不需要。
要点
- 基线HBsAg阳性患者中39%(9/23)发生HBV再激活。
- HBsAg阴性且抗-HBc阳性患者中无HBV再激活。
- 作者建议抗TNF治疗前筛查HBV,HBsAg阳性者应接受预防性抗病毒治疗。
核心结论
- 在接受TNF拮抗剂治疗的自身免疫病患者中,治疗前HBsAg阳性者HBV再激活率为39%,而HBsAg阴性且抗-HBc阳性者无再激活。
- 作者认为抗TNF治疗前应筛查HBV感染,HBsAg阳性患者应接受预防性抗病毒治疗,HBsAg阴性且抗-HBc阳性患者则不需要。
研究设计与样本
- 回顾性分析,数据来自Kaiser Permanente北加州数据库2001至2010年开始接受TNF拮抗剂治疗自身免疫病(皮肤科、风湿科或消化科)的8887例成人患者,随访至2012年12月。
- 52%的患者在治疗前接受了HBV筛查;采用多因素logistic回归分析与肝毒性3级或4级(HT ≥3)相关的因素。
主要发现
- 基线HBsAg阳性者23例,其中9例发生HBV再激活;基线HBV状态未知者4267例中2例发生HBV再激活。
- 基线HBsAg阴性且抗-HBc阳性者178例中无一例发生HBV再激活。
- HBsAg阳性患者中,接受预防性抗病毒治疗者HBV再激活1/5例,未接受者8/18例(P = .61)。
- 发生HBV再激活者无一例出现肝衰竭;HT ≥3发生于273例(2.7%),其中仅3例归因于HBV。
- 肝硬化与HT ≥3显著相关(P < .001)。
关键数值与推荐
- HBV再激活定义为以下之一:HBV DNA较基线升高>1 log、既往阴性者HBV DNA转为阳性、无基线水平时HBV DNA >2000 IU/mL、或逆转血清学转换。
- HT ≥3根据美国国家癌症研究所常见毒性标准定义。
临床怎么用
- 作者认为抗TNF治疗前应筛查HBV感染。
- 作者认为HBsAg阳性患者应接受预防性抗病毒治疗,而HBsAg阴性且抗-HBc阳性患者不需要。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Tumor necrosis factor (TNF) antagonists are the first-line treatment for many autoimmune diseases. However, they have been associated with reactivation of hepatitis B virus (HBV). We determined the rate of HBV reactivation and hepatotoxicity grade 3 or 4 (HT ≥3) in patients treated with an anti-TNF agent for an autoimmune disease. METHODS: We collected data from 8887 adult patients in the Kaiser Permanente Northern California database who began treatment with TNF antagonists for autoimmune diseases (dermatologic, rheumatologic, or gastrointestinal) from 2001 through 2010, followed through December 2012. We obtained data on HBV infection (52% of patients were screened for HBV before treatment), demographic features, comorbidities, and use of immunosuppressive agents. HBV reactivation was defined as 1 of the following: >1 log increase in HBV DNA, HBV DNA-positive when previously negative, HBV DNA >2000 IU/mL if no baseline level was available, or reverse seroconversion. HT ≥3 was defined according to the National Cancer Institute Common Toxicity Criteria. We performed multivariable logistic regression to identify factors associated with HT ≥3. RESULTS: Twenty-three patients tested positive for HB surface antigen (HBsAg) at baseline and 9 of these had HBV reactivation; of the 4267 patients with unknown HBV status at baseline, 2 had HBV reactivation. None of the 178 patients who were HBsAg negative and positive for the hepatitis B core antibody (anti-HBc+) had HBV reactivation. HBV reactivation occurred in 1/5 HBsAg+ patients who received prophylactic antiviral therapy and 8/18 who did not (P = .61). No one with HBV reactivation had liver failure. HT ≥3 occurred in 273 patients (2.7%), but only 3 cases were attributed to HBV. Cirrhosis was significantly associated with HT ≥3 (P < .001). CONCLUSION: In a retrospective analysis of patients treated with TNF antagonists for autoimmune diseases, we found HBV reactivation in 39% of patients who were HBsAg+ before therapy, but not in any patients who were HBsAg-negative and anti-HBc+ before therapy. Patients should be screened for HBV infection before anti-TNF therapy; HBsAg+ patients should receive prophylactic antiviral therapy, but not HBsAg-negative, anti-HBc+ patients.
引用
- Pauly MP, Tucker LY, Szpakowski JL, et al. Incidence of Hepatitis B Virus Reactivation and Hepatotoxicity in Patients Receiving Long-term Treatment With Tumor Necrosis Factor Antagonists. Clin Gastroenterol Hepatol. 2018. PMID: 29702293. doi:10.1016/j.cgh.2018.04.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。